SCHEMBL9909227

SCHEMBL9909227

N#Cc1ccc(-c2nccc3ccc(C(=O)O)cc23)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 3/20 0.47
KDM4C Q9H3R0 2/20 0.46
PLAU P00749 1/20 0.43
EGLN2 Q96KS0 1/20 0.40
RORC P51449 2/20 0.39
HSD17B14 Q9BPX1 1/20 0.38
MAP4K4 O95819 1/20 0.37
BTK Q06187 1/20 0.37
ADH5 P11766 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
RXRA P19793 1/20 0.37
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
ALK Q9UM73 1/20 0.36
PLA2G2D Q9UNK4 1/20 0.36
KDM4A O75164 1/20 0.36
KDM5A P29375 1/20 0.36
KDM5B Q9UGL1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909161 0.87 CYP11B1 (0.41) SLC22A12PLAUEGLN2KDM5AKDM5B
SCHEMBL9909306 0.85 HTR5A (0.51) PLAU
SCHEMBL9907375 0.82 KMO (0.53) KDM4CPLAURORCCSNK2A2CSNK2B
SCHEMBL9907436 0.79 PLAU (0.43) KDM4CPLAURORCADH5CSNK2A2
SCHEMBL9909158 0.77 KMT2A (0.46) SLC22A12KDM4CPLAU
SCHEMBL9909159 0.77 PLAU (0.43) SLC22A12KDM4CPLAUCSNK2A2CSNK2B
SCHEMBL9909253 0.74 HTR5A (0.55) SLC22A12KDM4CMAP4K4RXRAALK
SCHEMBL9907318 0.74 PLAU (0.50) KDM4CPLAUEGLN2CSNK2A2CSNK2B
SCHEMBL9907693 0.74 PLAU (0.50) KDM4CPLAUEGLN2RORCCSNK2A2
SCHEMBL15999132 0.73 MAP4K4 (0.52) SLC22A12KDM4CMAP4K4ADH5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E SLC22A12 1751/4885KDM4C 1366/4885PLAU 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.